noodls browser compatibility check

The security settings of your browser are blocking the execution of scripts.

To use noodls, javascript support must be enabled. Please change your browser's security settings to enable javascript.

If you have changed your browser's security settings, you can click here.

related announcements

News

Orrick, Herrington & Sutcliffe LLP

Microsoft Expands Global Data Center Capacity with 2 GW Data Center and[...]
Thomas Kean

Kean Introduces Landmark Bill to Put Mental Health Care on Equal[...]
OIT - Oregon Institute of Technology

Oregon Tech Awarded National Park Service Grant to Develop Accessible[...]

Healthcare

Unicycive Therapeutics Inc.

07/02/2026 | Press release | Distributed by Public on 07/02/2026 08:30

Material Event (Form 8-K)

Item 8.01 Other Events.

The Company had an ending cash balance of approximately $61.4 million as of June 30, 2026.

The preliminary results for the second quarter ended June 30, 2026, have been prepared by and are the responsibility of management. Neither our independent registered public accounting firm, nor any other independent accountants, have audited, reviewed, compiled or performed any procedures with respect to the preliminary results, nor have they expressed any opinion or any other form of assurance with respect thereto.

Unicycive Therapeutics Inc. published this content on July 02, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on July 02, 2026 at 14:30 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]